Wordt geladen...
Lenalidomide in follicular lymphoma
Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and...
Bewaard in:
| Gepubliceerd in: | Blood |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7290094/ https://ncbi.nlm.nih.gov/pubmed/32236519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001751 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|